Navigation Links
AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
Date:11/29/2011

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale.  These assets were generated by Epix Pharmaceuticals, Inc. and Amgen.

AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against S1P3 receptor by 50-fold.  It displayed efficacy in a DTH model with ED70 of 1.0 mpk.  AMG 277 was tested in FIH-enabling toxicology studies.    

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, LLP Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... endedChange %  30 September 201430 September 2013Turnover 546,011 , 534,641 ... 384,242 , 339,113 , 13.3 Hospital ... , 49.5 Medical Insurance Administration Service Income , ... and Accessories Sales , 94,580 , 142,683 ... , 9,219 , (68.4) Impairment Loss on Fixed ...
(Date:11/26/2014)... Nov. 26, 2014  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... investor conferences. On Tuesday, December 2, the ... Piper Jaffray Healthcare Conference.  D. Keith Grossman , ... on the company beginning at 11:30 a.m., Eastern Standard ...
(Date:11/26/2014)... , Nov. 26, 2014  Cohen, Placitella ... behalf of investors who purchased Nymox Pharmaceutical Corporation ... during the period from January 31, 2011 through ... whether Nymox and certain of its officers and ... in violation of Sections 10(b) and 20(a) of ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Dr. Diane Walder, one of the South ... Dr. Bridgit Nolan to her practice as a cosmetic ... her dermatology residency at the University of Miami Miller ... Nolan to join her practice because of her ... only does Dr. Nolan strive to provide the utmost ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Mirena ... move forward in New Jersey’s Bergen County Superior ... consolidated litigation established there is quickly approaching 1,300, ... on November 18th shows 1,293 lawsuits now pending ... lawsuits that allege complications resulting from spontaneous migration ...
(Date:11/28/2014)... 28, 2014 Miami's Plastic Surgery of ... Practice founder Dr. Jeffrey Epstein is excited ... a groundbreaking WordPress platform, the site is uniquely designed ... Currently, up to 75% of all prospective rhinoplasty patients ... people are logging on with smartphones, tablets, and laptops, ...
(Date:11/28/2014)... 28, 2014 Secura Consultants, based ... insurance marketing organizations in the country focused on ... protection marketplace. Secura Consultants is proud to offer ... Financial Group, a leading global financial company. , ... With the ownership interest comes the need for ...
Breaking Medicine News(10 mins):Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... study led by the University of Leicester has concluded that ... a doctor,s surgery helps to reduce emergency hospital admissions. ... at the University of Leicester revealed a correlation between patients ... admissions. The research, published in Emergency Medical Journal ...
... is available in French and Spanish . ... herpesviruses family, which also includes the herpes simplex virus and ... cause multiple sclerosis, a condition affecting the central nervous system, ... University of Granada scientists that analyzed the presence of ...
... team led by developmental biologist Professor Christophe Marcelle has nailed ... differentiate into specialised cells that form the skeletal muscles of ... journal Nature on Monday (May 16). Scientists ... processes that cause stem cells in the early embryo to ...
... by half in the radiation dose to which cardiac ... "feasible", according to an Israeli study. Results from ... at the International Conference of Non-Invasive Cardiovascular Imaging (ICNC) ... the world,s major scientific events in nuclear cardiology and ...
... study conducted by researchers in Connecticut, the Wii Fit offers ... and one that, because it is enjoyable, patients are ... COPD patients exercised at a relatively high percent of their ... indicating the Wii Fit may be a reasonable home-based exercise ...
... -- Patients who undergo angioplasty to unblock a clogged ... in a cardiac rehabilitation program afterwards, researchers report. ... are significant given the fact that more than 600,000 ... according to the American Heart Association (AHA). In ...
Cached Medicine News:Health News:Patients who see preferred doctor less likely to go for emergency hospital admission 2Health News:A virus similar to herpes could be a risk factor for multiple sclerosis 2Health News:Stem cell study could pave the way to treatment for age-related muscle wasting 2Health News:Halving the radiation dose in cardiac perfusion imaging is now 'feasible' 2Health News:Halving the radiation dose in cardiac perfusion imaging is now 'feasible' 3Health News:COPD patients may breathe easier, thanks to the Wii 2Health News:COPD patients may breathe easier, thanks to the Wii 3Health News:Cardiac Rehab Can Boost Survival After Angioplasty, Study Finds 2
... system is a long term, ... clinically proven design. Available in ... correct cruciate retaining configurations. In ... of identification keeps the user ...
... Oxinium (oxidized zirconium) isn't a new implant. ... Smith & Nephew. Wear debris can be ... almost nil, addressing the needs of the ... are all improved. Initially, Oxinium is available ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
... Posterior Stabilized knee system was ... polyethylene wear between all articulating ... stress associated with wear in ... balanced knee with normalized quadriceps ...
Medicine Products: